Accelerate Diagnostics (AXDX) announced the signing of a collaboration and quality agreement with Bruker Corporation (BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics’ Arc system, an innovative, automated positive blood culture sample preparation platform, with Bruker’s MALDI Biotyper sirius instruments and Sepsityper software for subsequent registration in both the US and EMEA markets.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXDX: